PARP1 and ovarian carcinoma: Positive findings from OPAL-C could significantly impact ovarian cancer treatment, particularly for patients who are ineligible for primary debulking surgery, and may lead to patients receiving less aggressive therapy (i.e., a chemotherapy-free PARP inhibitor) before surgery.